Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients

Table 4 Comparison of safety indexes between the two groups after medication

Characteristic (number, %)	Control group(n = 116)	Observation group(n = 116)	χ²	P
heart failure	4(3.45)	2(1.72)	0.681	0.408
renal adverse events	5(4.31)	4(3.45)	0.124	0.734
non-cardiovascular death	2(1.72)	1(0.86)	0.338	0.561
all-cause death	3(2.59)	1(0.86)	1.018	0.313

ISSN: 1758-5996